LEVOFLOXACIN INJECTION SOLUTION

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE)

Mevcut itibaren:

TEVA CANADA LIMITED

ATC kodu:

J01MA12

INN (International Adı):

LEVOFLOXACIN

Doz:

5MG

Farmasötik formu:

SOLUTION

Kompozisyon:

LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) 5MG

Uygulama yolu:

INTRAVENOUS

Paketteki üniteler:

50/100/150ML

Reçete türü:

Prescription

Terapötik alanı:

QUINOLONES

Ürün özeti:

Active ingredient group (AIG) number: 0131663001; AHFS:

Yetkilendirme durumu:

CANCELLED PRE MARKET

Yetkilendirme tarihi:

2017-02-09

Ürün özellikleri

_Page 1 of 71_
PRODUCT MONOGRAPH
Pr
TEVA-LEVOFLOXACIN
(levofloxacin)
250 mg, 500 mg and 750 mg Tablets
and
Pr
LEVOFLOXACIN INJECTION
(levofloxacin)
Sterile
5 mg/mL in 5% dextrose
Antibacterial Agent
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Canada
www.tevacanada.com
Submission Control No: 188951
Date of Revision:
February 22, 2016
_Page 2 of 71_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT
INFORMATION.........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
....................................................................................................
5
WARNINGS AND PRECAUTIONS
..................................................................................
5
ADVERSE REACTIONS
..................................................................................................
11
DRUG INTERACTIONS
..................................................................................................
15
DOSAGE AND ADMINISTRATION
..............................................................................
17
OVERDOSAGE
.................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 21
STORAGE AND STABILITY
..........................................................................................
26
DOSAGE FORMS, COMPOSITION AND
PACKAGING.............................................. 26
PART II: SCIENTIFIC INFORMATION
...............................................................................
28
PHARMACEUTICAL INFORMATION
..........................................................................
28
CLINICAL TRIALS
....................................................................................................